Clicky

Blueprint Medicines Corporation(BPMC)

Description: Blueprint Medicines Corporation, a biopharmaceutical company, focuses on the development of the highly selective kinase inhibitors for genomically defined cancer subsets. The company's lead drug candidates include BLU-285, which targets KIT Exon 17 and PDGFRa D842V, abnormally active receptor tyrosine kinase mutants for patients with systemic mastocytosis, a myeloproliferative disorder of the mast cells, and defined subsets of patients with gastrointestinal stromal tumor, as well as targets the KIT D816V mutation; and BLU-554, an orally available, potent, selective, and irreversible inhibitor, which targets FGFR4. It is also developing a drug candidate to target RET, a receptor tyrosine kinase that can becomes abnormally activated when a portion of the gene that encodes RET is joined to part of another gene; and RET resistant mutants that would arise from treatment with first generation therapies, as well as a program that targets rare genetic diseases. The company has a research, development, and commercialization agreement with Alexion Pharma Holding to research, develop, and commercialize drug candidates for an undisclosed activated kinase target, which is the cause of a rare genetic disease. The company was formerly known as Hoyle Pharmaceuticals, Inc. and changed its name to Blueprint Medicines Corporation in June 2011. Blueprint Medicines Corporation was founded in 2008 and is based in Cambridge, Massachusetts.


Keywords: Cancer Biopharmaceutical Cell Biology Gastrointestinal Protein Kinase Inhibitor Tyrosine Kinase Tyrosine Kinase Receptors Genetic Diseases Cell Signaling Rare Genetic Diseases Fibroblast Growth Factor Receptor Mastocytosis Rare Genetic Disease Systemic Mastocytosis Gastrointestinal Stromal Tumor Mast Cell Myeloproliferative Neoplasm Receptor Tyrosine Kinase Pdgfra

Home Page: www.blueprintmedicines.com

BPMC Technical Analysis

45 Sidney Street
Cambridge, MA 02139
United States
Phone: 617 374 7580


Officers

Name Title
Mr. Jeffrey W. Albers J.D., M.B.A., MBA Exec. Chairman
Ms. Kathryn Haviland Pres, CEO & Director
Mr. Alexis A. Borisy A.M. Co-Founder & Director
Mr. Michael Landsittel Chief Financial Officer
Dr. Percy H. Carter M.B.A., Ph.D. Chief Scientific Officer
Dr. Fouad Namouni M.D. Pres of R&D
Ms. Christina Rossi Chief Operating Officer
Dr. Christopher K. Murray Sr. VP of Technical Operations
Jenna Cohen Sr. Director & Head of Investor Relations
Ms. Tracey L. McCain Esq. Exec. VP, Chief Legal & Compliance Officer and Sec.

Exchange: NASDAQ

Country: US

Currency: US Dollar ($)

Forward PE: 0
Trailing PE: 0
Price-to-Book MRQ: 4.3665
Price-to-Sales TTM: 9.6137
IPO Date: 2015-04-30
Fiscal Year End: December
Full Time Employees: 602
Back to stocks